The benefits of antibiotic treatment during pregnancy are immediate, but there may be long-term risks to the developing child. Prior studies show an association between early life antibiotics and obesity, but few have examined this risk during pregnancy.
To evaluate the association of maternal antibiotic exposure during pregnancy on childhood BMI-z at 5 years, we conducted a retrospective cohort analysis. Using electronic health record data from seven health systems in PCORnet, a national distributed clinical research network, we included children with same-day height and weight measures who could be linked to mothers with vital measurements during pregnancy. The primary independent variable was maternal outpatient antibiotic prescriptions during pregnancy (any versus none). We examined dose response (number of antibiotic episodes), spectrum and class of antibiotics, and antibiotic episodes by trimester. The primary outcome was child age- and sex-specific BMI-z at age 5 years.
The final sample was 53,320 mother–child pairs. During pregnancy, 29.9% of mothers received antibiotics. In adjusted models, maternal outpatient antibiotic prescriptions during pregnancy were not associated with child BMI-z at age 5 years (β = 0.00, 95% CI −0.03, 0.02). When evaluating timing during pregnancy, dose-response, spectrum and class of antibiotics, there were no associations of maternal antibiotics with child BMI-z at age 5 years.
In this large observational cohort, provision of antibiotics during pregnancy was not associated with childhood BMI-z at 5 years.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $64.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
“The views expressed in this article do not necessarily represent the views of the US Government, the Department of Health and Human Services or the National Institutes of Health.”
List of members of the PCORnet Antibiotics and Childhood Growth Study Group is listed below Acknowledgement
All statements in this manuscript are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governor, or Methodology Committee. The PCORnet Childhood Antibiotic Study Team includes a diverse group of investigators, research staff, clinicians, community members, and parent caregivers. All members of the team including the study’s Executive Antibiotic Stakeholder Advisory Group (EASAG) contributed to the study design, data acquisition, and interpretation of results. The Study Team would like to thank the leaders of the participating PCORnet Clinical Data Research Networks (CDRNs), Patient Powered Research Networks (PPRNs), and PCORnet Coordinating Center as well as members of the PCORI team for their support and commitment to this project.
Members of the PCORnet Antibiotics and Childhood Growth Study Group:
David Arterburn12, Lauren P. Cleveland4, Jonathan Finkelstein13, Stephanie L. Fitzpatrick14, Andrea Goodman15, Michael Horberg16, Jenny Ingber17, Kathleen Murphy17, Holly Landrum Peay18, Pedro Rivera19, Juliane S. Reynolds6, Jessica L. Sturtevant6, Ivette Torres20
This work was supported through the Patient-Centered Outcomes Research Institute (PCORI) Program Award (OBS-1505-30699).